SCNC

Home Hardware Stores Limited Named Presenting Sponsor of the Skills Canada National Competition

Retrieved on: 
Thursday, March 21, 2024
SCC, Growth, Environment, Partnership, CAF, Student, SCNC, Skill, Home Hardware, Human, Video game

OTTAWA, March 21, 2024 (GLOBE NEWSWIRE) -- Skills/Compétences Canada (SCC), a not-for-profit organization that actively promotes careers in the skilled trades and technologies to youth and their communities in Canada, is proud to announce that Home Hardware Stores Limited, Canada’s largest Dealer-owned home improvement retailer, has signed on as a Presenting Sponsor of the Skills Canada National Competition (SCNC) 2024, in Québec City.

Key Points: 
  • OTTAWA, March 21, 2024 (GLOBE NEWSWIRE) -- Skills/Compétences Canada (SCC), a not-for-profit organization that actively promotes careers in the skilled trades and technologies to youth and their communities in Canada, is proud to announce that Home Hardware Stores Limited, Canada’s largest Dealer-owned home improvement retailer, has signed on as a Presenting Sponsor of the Skills Canada National Competition (SCNC) 2024, in Québec City.
  • “Home Hardware Stores Limited is proud to join forces with Skills/Compétences Canada in fostering a passion for trades and technology in students,” said Kevin Macnab, President and CEO, Home Hardware Stores Limited.
  • SCC is pleased to work with Home Hardware Stores Limited for this year’s upcoming Skills Canada National Competition.
  • “This partnership with Home Hardware Stores Limited and Skills/Compétences Canada has highlighted the meaningful impact of skilled trades and technologies on our society.

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Tuesday, March 12, 2024
The Orange Book, Patent Cooperation Treaty, Agitation, Administration, Conference call, Type, PCT, Conference, Database, Schizophrenia, Intelligence, Caregiver, Webcast, Patient, DSM-IV codes, Neuroscience, Fast Track, Food and Drug Administration, CMC, Wind, Orange Book, SCNC, Positive, Microsatellite instability, Dexmedetomidine, Clinical trial, Therapy, Safety, Patent, Research and development, Collection, FDA, Approved drug, Dementia, CAD, Food, Pharmaceutical industry

NEW HAVEN, Conn., March 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today provided an update on its late-stage TRANQUILITY and SERENITY clinical programs. In addition, the Company reported its financial results for the fourth quarter and full year 2023.

Key Points: 
  • In addition, the Company reported its financial results for the fourth quarter and full year 2023.
  • Net Revenue: Net revenue from IGALMI was $376,000 for the fourth quarter of 2023, compared to $238,000 for the same period in 2022.
  • Net Loss: BioXcel Therapeutics had a net loss of $22.3 million for the fourth quarter of 2023, compared to a net loss of $54.8 million for the same period in 2022.
  • ET to provide an update on recent operational highlights and to discuss its fourth quarter and full year 2023 financial results.

myFootpath Partners with CAEL to Expand Services to ReEngage and Support Students

Retrieved on: 
Monday, February 26, 2024
SCNC, Student, Education, Partnership, Learning, National Student Clearinghouse, Council, Organization, Employment, Credit, Experience, Nursing

CHICAGO, Feb. 26, 2024 /PRNewswire-PRWeb/ -- myFootpath, a leading higher education service provider for 20+ years, has announced a new collaboration with CAEL (Council for Adult and Experiential Learning), a national nonprofit organization located in Indianapolis, Indiana that helps adult learners navigate on- and off-ramps between education and employment to enable economic mobility for all adults. The organizations share a common mission to transform lives by supporting nontraditional students who may have stumbled along the path to degree completion. In this collaborative effort, myFootpath will support CAEL's Credit Predictor Pro tool. Credit Predictor Pro helps higher education institutions recruit adult learners by ensuring those learners are aware of and can receive credit for past training and experience.

Key Points: 
  • myFootpath and CAEL announce a collaboration to support nontraditional adult learners in obtaining college credit for prior experience, aiming to address the increasing demand for tailored services for stop-out students and facilitate faster degree completion.
  • The organizations share a common mission to transform lives by supporting nontraditional students who may have stumbled along the path to degree completion.
  • In this collaborative effort, myFootpath will support CAEL's Credit Predictor Pro tool.
  • - JT Allen, Founder and CEO of myFootpath
    Today's announcement underscores the significant and growing demand for support services tailored to stop-out students.

BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)

Retrieved on: 
Monday, February 12, 2024
New product development, American Cancer Society, SCNC, Medicine, Prostate cancer, Intelligence, Adenocarcinoma, FDA, Food, CPI, Therapy, Patient, Microsatellite instability, Survival, Pharmaceutical industry

NEW HAVEN, Conn., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of BXCL701 in combination with a CPI for the treatment of patients with metastatic small cell neuroendocrine prostate cancer (SCNC) with progression on chemotherapy and no evidence of microsatellite instability. The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly. Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review. 

Key Points: 
  • The FDA grants Fast Track designation to facilitate the development and expedite the review of medicines to treat serious conditions, fill unmet medical needs, and bring promising medicines to patients more quickly.
  • Therapies granted this designation are given the opportunity for more frequent interactions with the FDA, a rolling review, and potential eligibility for accelerated approval and priority review.
  • At the same time, it further validates the unique AI-based drug re-innovation approach that we used to discover this asset,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics.
  • “We are encouraged by the potential of BXCL701, which has demonstrated clinical proof of concept in both SCNC and adenocarcinoma.

BioXcel Therapeutics Announces Completion of Patient Enrollment in Safety Portion of Investigator-Sponsored Phase 2 Relapsed Pancreatic Cancer Trial of BXCL701 in Combination with KEYTRUDA®

Retrieved on: 
Tuesday, February 6, 2024
Tumor microenvironment, Intelligence, Immunotherapy, Survival, Prostate cancer, Human, Pancreatic cancer, PDAC, Opinion, American Cancer Society, NK, Society, Patient, Safety, Macrophage, New product development, Medicine, United, SCNC, Therapy, Journal, Merck, Neoplasm, Cancer, Adenocarcinoma, Merck & Co., Pharmaceutical industry

NEW HAVEN, Conn., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced the completion of patient enrollment in the safety lead-in portion of the investigator-sponsored Phase 2 trial of BXCL701 in combination with KEYTRUDA® (pembrolizumab) in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). BioXcel Therapeutics, through its OnkosXcel Therapeutics immuno-oncology subsidiary, is collaborating with Georgetown Lombardi’s Dr. Louis M. Weiner, director of the cancer center, and Dr. Benjamin Weinberg, the study’s principal investigator. BioXcel Therapeutics and Merck & Co. are providing BXCL701 and KEYTRUDA for the trial, respectively.

Key Points: 
  • BioXcel Therapeutics and Merck & Co. are providing BXCL701 and KEYTRUDA for the trial, respectively.
  • The trial is evaluating BXCL701, an investigational, oral innate immune activator designed to inflame the tumor microenvironment and thereby augment the activity of checkpoint inhibitors.
  • “Pancreatic cancer represents a significant unmet medical need, ranking as the third-leading cause of cancer deaths1, yet remains an exceptionally difficult cancer to treat.
  • This Phase 2 trial marks the third cold tumor setting where we are testing BXCL701 in combination with KEYTRUDA.

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) of Adenocarcinoma Phenotype

Retrieved on: 
Wednesday, November 8, 2023
Adenocarcinoma, FDA, Intelligence, Taxane, Progression-free survival, Trial of the century, MCRPC, Lymph, Pembrolizumab, Data, Prostate cancer, Liver, BID, Phenotype, Disease, Rectum, Neoplasm, Partnership, Histology, September 6, RECIST, Tumor microenvironment, Safety, SCNC, Therapy, Patient, OS, CTC, Pharmaceutical industry, HAVEN

NEW HAVEN, Conn., Nov. 08, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in patients with metastatic castration-resistant prostate cancer (mCRPC) of adenocarcinoma phenotype, the most common form of the disease. As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months (95% CI 9.6–NR), and a 12-month survival rate of 59%.

Key Points: 
  • As of a September 6, 2023 data cutoff, evaluable patients with adenocarcinoma (n=29) showed a median OS of 15.5 months (95% CI 9.6–NR), and a 12-month survival rate of 59%.
  • “Therefore, we are highly encouraged by these combination data bearing in mind historical data with checkpoint inhibitor monotherapy.
  • Approximately 80% of mCRPC cases are of the adenocarcinoma phenotype, which represent approximately 46,128 patients.
  • The Company is continuing to actively evaluate strategic options for OnkosXcel Therapeutics, including potential financing, strategic partnership, or M&A.

Changing Enrollment Behaviors, Continued Distrust Punctuate Higher Ed Landscape in 2023

Retrieved on: 
Wednesday, October 25, 2023
National Student Clearinghouse, National Center for Science and Engineering Statistics, Education, Labour, Government, Bureau of Labor Statistics, Enrollment, Workforce, Statistics, Bureau, National Center for Education Statistics, BLS, Student, School, AI, SCNC, Nursing, Gallup

Lenexa, Kan. (October 25, 2023), Oct. 25, 2023 (GLOBE NEWSWIRE) -- Today, EducationDynamics , a leading enrollment management agency specializing in higher education, released its highly anticipated " 2023 Higher Ed Landscape " report.

Key Points: 
  • Lenexa, Kan. (October 25, 2023), Oct. 25, 2023 (GLOBE NEWSWIRE) -- Today, EducationDynamics , a leading enrollment management agency specializing in higher education, released its highly anticipated " 2023 Higher Ed Landscape " report.
  • Now in its 4th year, the comprehensive report delves into the evolving dynamics between higher education, the changing labor market and prospective students.
  • This year, the industry continues to face challenges at almost every level, and enrollment remains below pre-2020 levels.
  • "Our '2023 Higher Ed Landscape Report' not only details the evolving nature of education in America, but also provides institutional leadership with insight into the priorities of their largest stakeholders: prospective students,” said EducationDynamics CEO Bruce Douglas.

BioXcel Therapeutics Reports Positive Overall Survival Results from Single-Arm, Open-Label Phase 2 Trial of BXCL701 in Patients with Small Cell Neuroendocrine Prostate Cancer

Retrieved on: 
Tuesday, October 10, 2023
Neoplasm, Partnership, Clinical Science (journal), Intelligence, Pembrolizumab, BID, CPI, UCSF, Trial of the century, SCNC, Safety, University, Survival, CTC, Disease, FDA, Therapy, RECIST, Webcast, Carcinoma, Associate, Prostate cancer, Progression-free survival, University of California, San Francisco, Patient, Pharmaceutical industry, Medicine

NEW HAVEN, Conn., Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced positive overall survival (OS) data from its Phase 2 trial of BXCL701, the Company's investigational oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in patients with small cell neuroendocrine prostate cancer (SCNC). As of a data cutoff of September 6, 2023, evaluable patients with SCNC (n=28) showed a median OS of 13.6 months (95% CI 10.9–NR), and a 12-month survival rate of 56.5%.

Key Points: 
  • “OS is the most meaningful measure by which the effectiveness of an oncology treatment is evaluated.
  • In 2023, there will be an estimated 288,3002 new patients with prostate cancer in the United States, with approximately 11,532 patients progressing to SCNC.
  • ET to discuss the data results from the Phase 2 trial of BXCL701.
  • Financial and other important information is routinely posted on and accessible through the Investors sections of its website at www.bioxceltherapeutics.com .

Government of Canada Announces Funding for Skills/Compétences Canada under the Canadian Apprenticeship Strategy

Retrieved on: 
Friday, July 14, 2023
Workforce, SCC, Minister of Employment, Workforce Development and Disability Inclusion, SCNC, Government, Employment, Student, Workforce development, Government of Canada

This funding will go towards promoting the rewarding careers that are available in the skilled trades and technologies to our country’s youth.

Key Points: 
  • This funding will go towards promoting the rewarding careers that are available in the skilled trades and technologies to our country’s youth.
  • Skills/Compétences Canada provides hands-on experience in skilled trades and technologies to youth through its many programs and events, including its flagship event the Skills Canada National Competition (SCNC).
  • This event includes over 40 skilled trade and technology competitions for more than 500 competitors from across Canada.
  • "We are grateful for the government's continued support of SCC's work to strengthen Canada's future skilled trades workforce."

The Official Members of WorldSkills Team Canada 2024 Are Announced!

Retrieved on: 
Tuesday, July 4, 2023
Workforce, WorldSkills, SCC, WSTC, SCNC

OTTAWA, July 04, 2023 (GLOBE NEWSWIRE) -- Skills/Compétences Canada (SCC), a not-for-profit organization that actively promotes careers in skilled trades and technologies, is proud to officially announce the 28 members of WorldSkills Team Canada 2024.

Key Points: 
  • OTTAWA, July 04, 2023 (GLOBE NEWSWIRE) -- Skills/Compétences Canada (SCC), a not-for-profit organization that actively promotes careers in skilled trades and technologies, is proud to officially announce the 28 members of WorldSkills Team Canada 2024.
  • They will begin their training to prepare for the 47th WorldSkills Competition, in Lyon, France, which will be held in September 2024.
  • Here are the official members of WorldSkills Team Canada 2024:
    Following the 2023 Skills Canada National Competition (SCNC) held in Winnipeg last May, the highest ranking, age eligible participant in each identified Skill Area, was selected to participate in the next WorldSkills Competition.
  • WorldSkills Team Canada (WSTC) 2024 will meet for the first time next Fall, where they will begin preparations for the 47th WorldSkills Competition.